Related Experiment Video
Updated: Jul 29, 2025
Author Spotlight: Collecting the Brain and Serum from the Same Mice Fetus to Study Brain Tumor Development
Published on: May 17, 2024
Difluoromethylornithine (DFMO) and Neuroblastoma: A Review
Adarsh Vardhan Tangella1, Ashwin S Gajre2, Punith Chowdary Chirumamilla3
1Internal Medicine, Andhra Medical College and King George Hospital, Visakhapatnam, IND.
Abstract:
Neuroblastoma is a type of cancer that affects the sympathetic nervous system and is the most common extracranial solid tumor in children. Difluoromethylornithine (DFMO) is a drug that has shown promise as a treatment option for high-risk neuroblastoma. This review aims to provide an overview of the current research on the use of DFMO in neuroblastoma treatment. The review includes a discussion of the mechanisms of action of DFMO, as well as its potential for use in combination with other treatments such as chemotherapy and immunotherapy. The review also examines the current clinical trials involving DFMO in high-risk neuroblastoma patients and provides insights into the challenges and future directions for the use of DFMO in neuroblastoma treatment. Overall, the review highlights the potential of DFMO as a promising therapy for neuroblastoma and highlights the need for further research to fully understand its potential benefits and limitations.
Insights
Difluoromethylornithine (DFMO) shows promise for treating high-risk neuroblastoma, a common childhood cancer. Further research is needed to fully understand DFMO
Area of Science:
- Pediatric Oncology
- Pharmacology
Background:
- Neuroblastoma is the most common extracranial solid tumor in children, affecting the sympathetic nervous system.
- High-risk neuroblastoma presents a significant therapeutic challenge.
Purpose of the Study:
- To review current research on Difluoromethylornithine (DFMO) for neuroblastoma treatment.
- To explore DFMO's mechanism of action, combination therapies, and clinical trial status.
Main Methods:
- Literature review of existing research on DFMO in neuroblastoma.
- Analysis of preclinical and clinical data regarding DFMO efficacy and safety.
- Examination of combination strategies with chemotherapy and immunotherapy.
Main Results:
- DFMO demonstrates potential as a targeted therapy for neuroblastoma.
- Combination therapies involving DFMO may enhance treatment outcomes.
- Ongoing clinical trials are evaluating DFMO in high-risk neuroblastoma patients.
Conclusions:
- DFMO is a promising therapeutic agent for neuroblastoma.
- Further investigation is required to optimize DFMO use and understand its full potential and limitations in neuroblastoma treatment.
